Three-Year Drug Survival 80% for Ixekizumab in Real-World Patients With Plaque Psoriasis

Among patients with moderate-to-severe plaque psoriasis prescribed ixekizumab in a real-world setting, 80% were still on the medication 3 years later, according to study findings published in Expert Opinion on Biological Therapy.

The study was a retrospective analysis of 306 patients with chronic plaque psoriasis who had received at least one dose of ixekizumab before December 2018. Researchers were interested in drug survival of ixekizumab in a multicenter, real-world setting.

Among patients prescribed ixekizumab, rates of drug survival were 92.11% at 12 months, 83.85% at 24 months, and 80.19% at 36 months, according to the study.

When investigators considered the influence of predictive factors on drug withdrawal, they found the probability of drug withdrawal was higher (2.34 hazard ratio) among patients who had already received an anti-interleukin-17 agent compared with patients who had no history of biologic treatment.

“We found that ixekizumab is a biological agent characterized by long-term effectiveness, not influenced by several clinical factors, and associated with a good safety profile,” reported the research team, which was based in Italy.

Reference:
Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin Biol Ther. Published online March 20, 2023. doi:10.1080/14712598.2023.2193288